CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer.

about

Application of Genome Editing Techniques in Immunology.KEAP1 Editing Using CRISPR/Cas9 for Therapeutic NRF2 Activation in Primary Human T Lymphocytes.Gastric cancer: Basic aspects.Tim-3 expression and its role in hepatocellular carcinoma

P2860

Q47482062-200D0BB3-89DC-46EB-9CC6-7F521F046060 Q48204957-5646A4AF-63A3-4FCA-BF65-4995A6318666 Q50168318-B7A604B7-65FF-47B0-83D0-54870B61524D Q57476217-37849F23-1A18-428B-911A-F1D5A8451328

P2860

CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer.

Item

http://www.wikidata.org/entity/Q40336060

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

CRISPR-Cas9-mediated disruptio ...... f EBV positive gastric cancer.

@en

type

Item

label

CRISPR-Cas9-mediated disruptio ...... f EBV positive gastric cancer.

@en

prefLabel

CRISPR-Cas9-mediated disruptio ...... f EBV positive gastric cancer.

@en

P1476

CRISPR-Cas9-mediated disruptio ...... f EBV positive gastric cancer.

@en

P2093

Baorui Liu

http://www.w3.org/2001/XMLSchema#string

Bian Hu

http://www.w3.org/2001/XMLSchema#string

Fangjun Chen

http://www.w3.org/2001/XMLSchema#string

Fanyan Meng

http://www.w3.org/2001/XMLSchema#string

Huizi Sha

http://www.w3.org/2001/XMLSchema#string

Jia Wei

http://www.w3.org/2001/XMLSchema#string

Jie Shao

http://www.w3.org/2001/XMLSchema#string

Juan Du

http://www.w3.org/2001/XMLSchema#string

Lin Li

http://www.w3.org/2001/XMLSchema#string

Naiqing Ding

http://www.w3.org/2001/XMLSchema#string

P2860

Cas9 as a versatile tool for engineering biology

A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity

Genomic assays for Epstein-Barr virus-positive gastric adenocarcinoma

In situ expression and significance of B7 costimulatory molecules within tissues of human gastric carcinoma

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

Pembrolizumab for the treatment of non-small-cell lung cancer

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

P304

e1249558

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/2162402X.2016.1249558

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28197365

http://www.w3.org/2001/XMLSchema#string

P921

CRISPR

P932

5283615

http://www.w3.org/2001/XMLSchema#string

CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer.

about

P2860

P2860

CRISPR-Cas9-mediated disruption of PD-1 on human T cells for adoptive cellular therapies of EBV positive gastric cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P932